Abivax SA (ABVX)
NASDAQ: ABVX · IEX Real-Time Price · USD
10.70
-0.10 (-0.93%)
Dec 29, 2023, 4:30 PM EST - Market closed
Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Abivax SA
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Marc M. P. de Garidel M.B.A. |
Contact Details
Address: 7 Bd Haussmann Paris, I0 75009 France | |
| Phone | 01 53 83 09 63 |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.60 |
| CIK Code | 0001956827 |
| ISIN Number | US00370M1036 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 30, 2023 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 23, 2023 | 424B4 | Prospectus |
| Oct 20, 2023 | FWP | Free Writing Prospectus |
| Oct 19, 2023 | EFFECT | Notice of Effectiveness |
| Oct 19, 2023 | EFFECT | Notice of Effectiveness |
| Oct 19, 2023 | CERT | Certification by an exchange approving securities for listing |
| Oct 18, 2023 | 8-A12B | Registration of securities |
| Oct 18, 2023 | F-1/A | [Amend] Registration statement for certain foreign private issuers |